# Cannabis and Parkinson’s Disease: What a New Evidence Review Shows > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-sativa-parkinsons-motor-symptoms-review/ > **Published:** 2026-07-23T21:29:38-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:48:29-04:00 > **Clinical Summary:** Explore the latest evidence on cannabis sativa Parkinsons motor symptoms showing no motor benefit in a rigorous systematic review. --- CED Clinical Relevance #82 Rigorous Review, Sobering Cannabis Signal A July 23, 2026 PRISMA-guided, PROSPERO-registered systematic review evaluated six plant-derived therapies for Parkinson’s disease. It graded the evidence for Cannabis sativa on motor symptoms as Grade A for no benefit, while a different plant compound, Mucuna pruriens, showed Grade A evidence for motor improvement comparable to levodopa. Clinical Insight | CED Clinic A systematic review published July 23, 2026 in the Journal of Neural Transmission asked a direct question: across the plant-derived therapies patients and clinicians already discuss for Parkinson’s disease, which ones have real clinical evidence behind them, and how strong is that evidence. The review followed PRISMA 2020 reporting guidelines and was registered in advance with PROSPERO, which limits the chance that the authors changed their methods after seeing the results. Twenty-three included studies covered six plant-derived therapies: Mucuna pruriens, Apium graveolens, Curcuma longa, Bacopa monnieri, Glycine max, and Cannabis sativa. For cannabis specifically, the review’s grading was sobering rather than encouraging. Cannabis sativa was rated Grade A, the review’s highest evidence-quality tier, for showing no motor benefit, with non-motor outcomes rated inconclusive. That result deserves to be reported as plainly as any positive finding would be. Parkinson’s DiseaseSystematic ReviewPlant-Derived TherapiesCannabis SativaMotor Symptoms Audience Movement-disorder neurologists, primary care and cannabis-medicine clinicians, and Parkinson’s patients or caregivers evaluating plant-derived adjunctive options. Primary Topic A July 23, 2026 systematic review grading the clinical evidence for six plant-derived therapies, including Cannabis sativa, in Parkinson’s disease. Source [Read the full source](https://pubmed.ncbi.nlm.nih.gov/42489905/) Table of Contents - [Cannabis and Parkinson’s Motor Symptoms: What a New Systematic Review Actually Shows](#Cannabis_and_Parkinson8217s_Motor_Symptoms_What_a_New_Systematic_Review_Actually_Shows) - [How to Read a Multi-Therapy Systematic Review Without Overclaiming or Dismissing It](#How_to_Read_a_Multi-Therapy_Systematic_Review_Without_Overclaiming_or_Dismissing_It)[Four questions worth asking before you trust a multi-therapy grade](#Four_questions_worth_asking_before_you_trust_a_multi-therapy_grade) - [The Same Study Can Mean Different Things Depending on the Question Being Asked](#The_Same_Study_Can_Mean_Different_Things_Depending_on_the_Question_Being_Asked)[What This Means If You Are Living With Parkinson’s](#What_This_Means_If_You_Are_Living_With_Parkinson8217s) - [What a Responsible Clinician Can Say About This Finding](#What_a_Responsible_Clinician_Can_Say_About_This_Finding) - [Why a Cautious Reader Should Slow Down](#Why_a_Cautious_Reader_Should_Slow_Down) - [Where the Methodologic Pressure Points Are](#Where_the_Methodologic_Pressure_Points_Are) - [How This Fits With Earlier CED Coverage on Cannabis and Parkinson’s](#How_This_Fits_With_Earlier_CED_Coverage_on_Cannabis_and_Parkinson8217s) - [What Changes in the Exam Room](#What_Changes_in_the_Exam_Room) - [What Better Evidence Needs Next](#What_Better_Evidence_Needs_Next) - [How This Review Could Be Distorted, and What It Actually Says](#How_This_Review_Could_Be_Distorted_and_What_It_Actually_Says) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) ## Cannabis and Parkinson’s Motor Symptoms: What a New Systematic Review Actually Shows A new PRISMA-guided, PROSPERO-registered systematic review graded the clinical evidence behind six plant-derived Parkinson’s therapies. Cannabis sativa was rated Grade A, the review’s highest evidence tier, for showing no motor benefit. A different plant compound, Mucuna pruriens, was rated Grade A for motor improvement comparable to levodopa. Here is what the review actually found, and what it does not settle. What This Study Teaches Us This review teaches that evidence quality and treatment benefit are two separate questions. A therapy can be studied rigorously enough to earn a high evidence grade while that grade confirms an absence of benefit rather than a presence of one, and Cannabis sativa’s motor-symptom result in this review is exactly that case. Why This Matters Patients with Parkinson’s disease frequently ask whether cannabis can help with tremor, rigidity, or bradykinesia, often based on general cannabis-wellness messaging rather than movement-disorder-specific data. A rigorous, preregistered review that directly graded cannabis against five other plant-derived options gives clinicians a much firmer basis for that conversation than anecdote or extrapolation from other conditions, and it does so without dismissing plant-derived approaches broadly, since several other compounds in the same review scored well. Study Snapshot Study Type Systematic review, PRISMA 2020 guidelines, PROSPERO registered Registration PROSPERO CRD420261276805 Included Studies 23 studies across six plant-derived therapies Therapies Evaluated Mucuna pruriens, Apium graveolens, Curcuma longa, Bacopa monnieri, Glycine max, Cannabis sativa Cannabis Sativa Finding No motor benefit (Grade A evidence); non-motor outcomes inconclusive Strongest Overall Finding Mucuna pruriens: Grade A evidence for motor improvement comparable to levodopa, increased ON time without worsening dyskinesia Journal Journal of Neural Transmission (Vienna) Published July 23, 2026 PMID 42489905 DOI 10.1007/s00702-026-03239-4 Authors Sukmueng N, Phokaewvarangkul O, Bhidayasiri R Clinical Use Evidence-grading reference for patient counseling, not standalone treatment proof Clinical Bottom Line This review does not support using Cannabis sativa specifically for Parkinson’s motor symptoms, based on Grade A evidence of no benefit, while it does support a stronger conversation about Mucuna pruriens and, with more caution, several other plant-derived options for specific symptom domains. What This Review Actually Evaluated The review was not a single trial of cannabis in Parkinson’s disease. It was a preregistered synthesis of 23 existing studies across six different plant-derived therapies, each assessed for its effect on motor symptoms, non-motor symptoms, and motor complications such as dyskinesia. That design matters for how the cannabis finding should be read. The authors were not screening for a positive cannabis result. They were grading the existing evidence base for six plant compounds side by side, using the same methodology for each. Why the Cannabis Sativa Result Deserves Attention The review rated the evidence on Cannabis sativa and Parkinson’s motor symptoms as Grade A, its highest evidence-quality tier, and that grade supported a finding of no motor benefit. Non-motor outcomes were rated inconclusive rather than positive or negative. A Grade A rating here is not a compliment to cannabis. It means the underlying studies were consistent and well-designed enough for the reviewers to be confident in a negative motor-symptom result, which is a more decisive statement than a single small or mixed-quality study could make. How Mucuna Pruriens Compared in the Same Review Mucuna pruriens, a legume that naturally contains levodopa’s precursor molecule, received Grade A evidence for motor improvement comparable to levodopa itself, including increased ON time without worsening dyskinesia, plus Grade B evidence for reducing dyskinesia. Placing this result next to the cannabis finding is useful precisely because both were assessed with the same review methodology. It shows the review was capable of identifying a strong positive signal when the underlying studies supported one, which strengthens confidence in its negative cannabis finding rather than suggesting a biased or dismissive review. What an Evidence Grade Does and Does Not Tell You The authors were explicit that their grading reflects study hierarchy and methodological rigor, not the certainty of the clinical effect itself. A Grade A rating means the reviewers trust the finding, whether that finding is positive or negative, more than they would trust a lower-graded result. This distinction matters because patients sometimes hear ‘evidence graded A’ and assume it means ‘strong benefit.’ In this review, the opposite is true for cannabis specifically. It means strong confidence in an absence of motor benefit. Where the Other Plant Therapies Landed Apium graveolens (celery seed extract) was rated Grade B for improving motor symptoms, sleep, and quality of life. Bacopa monnieri was rated Grade B for improving emotional symptoms. Curcuma longa (turmeric) and Glycine max (soybean) were rated Grade C, a lower confidence tier, for autonomic and non-motor symptom improvement and for increased ON time with reduced dyskinesia, respectively. The review’s overall message was that plant-derived therapies may offer symptom-specific benefits, but the authors cautioned that interpretation should be careful and that larger, well-designed randomized trials are still needed across the board. How Strong Is This Evidence? This is a preregistered, PRISMA-guided systematic review synthesizing 23 studies across six therapies, which is a meaningfully stronger evidence structure than any single trial. The specific Cannabis sativa motor-symptom conclusion was graded A, the review’s top tier, meaning the reviewers judged the underlying cannabis studies to be consistent and well-designed enough to support a confident conclusion. Where This Paper Deserves Skepticism A systematic review is only as strong as the studies it pools, and the abstract does not report how many of the 23 total studies specifically addressed cannabis versus the other five plant therapies, what cannabis products or doses were used, or how non-motor symptoms were measured across those cannabis studies. Readers should also note this is one review, not a single definitive trial, and its grading reflects the current literature rather than an unchangeable final answer. What This Paper Does Not Show This review does not show that cannabis is harmful in Parkinson’s disease, and it does not show that cannabis has no role at all in Parkinson’s care. It specifically addresses motor symptoms, rating non-motor outcomes as inconclusive rather than negative. It does not identify a specific cannabis product, dose, route, or THC-to-CBD ratio, and it does not evaluate cannabis for indications outside motor and non-motor Parkinson’s symptoms, such as the pain, sleep, or nocturia outcomes examined in separate observational research. How This Fits With the Broader Clinical Conversation CED Clinic has previously covered cannabis and Parkinson’s disease from two other angles: preclinical neuroprotection data on cannabis seed compounds and dopaminergic cell protection, and an observational study of pain, sleep, and nighttime urination improvements in patients starting [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/). Neither of those pieces addressed motor-symptom efficacy directly, which is exactly the gap this new systematic review fills. Read together, the picture is more nuanced than either ‘cannabis helps Parkinson’s’ or ‘cannabis has no place in Parkinson’s care.’ The current evidence base points toward cannabis having a more defensible role in non-motor symptom management and possible cellular neuroprotection than in treating motor symptoms directly, and this review is the most rigorous evidence yet on that specific motor-symptom question. Dr. Caplan’s Take *I want cannabis to be evaluated by the same evidentiary standard as any other therapy I recommend, and this review is a good example of that standard working as intended. A Grade A finding of no motor benefit is not a failure of the review process. It is the review process doing its job.* *When a Parkinson’s patient asks me about cannabis for tremor or rigidity, this study gives me a clearer, more honest answer than I had before: the best current evidence does not support it for motor symptoms. That does not end the conversation about cannabis in Parkinson’s care, since sleep, pain, mood, and possible neuroprotective mechanisms remain open and worth discussing, but it does mean I will not oversell cannabis as a motor-symptom treatment.* What a Careful Reader Should Take Away A careful reader should take away that this review strengthens, rather than weakens, the case for [evidence-based cannabis](https://cedclinic.com/jama-cannabis-review-physician-analysis/) counseling in Parkinson’s disease: it rules out motor-symptom benefit with real confidence while leaving non-motor symptom management and neuroprotection as open, separately evidenced questions. Evidence Interpretation Guide ## How to Read a Multi-Therapy Systematic Review Without Overclaiming or Dismissing It Reviews that grade several therapies at once are easy to misread in either direction, either by assuming every included therapy performed the same, or by treating one negative finding as proof that the whole plant-derived category is worthless. The right approach is to read each therapy’s grade on its own terms, and to separate the quality of the evidence from the direction of the result. ### Four questions worth asking before you trust a multi-therapy grade **What specific outcome was graded?**This review graded Cannabis sativa on motor symptoms specifically. Non-motor symptoms received a separate, inconclusive rating, and outcomes like pain, sleep, and urinary symptoms were not part of this review at all. **Does the evidence grade describe confidence or benefit?**A high grade reflects how much the reviewers trust the finding, not automatically how positive that finding is. Here, Grade A described confidence in an absence of motor benefit. **How does this therapy compare to others graded the same way?**Comparing cannabis to Mucuna pruriens, both reviewed under the same methodology, shows the review was capable of grading a strong positive result, which supports taking its negative cannabis finding seriously rather than assuming reviewer bias. **What clinical action is actually justified?**This review supports more honest counseling about motor-symptom expectations for cannabis in Parkinson’s disease. It does not justify abandoning cannabis conversations about non-motor symptoms, which remain a separate, inconclusive question here. The Research Question Across six plant-derived therapies studied in Parkinson’s disease, how strong is the clinical evidence for each, including Cannabis sativa, on motor symptoms, non-motor symptoms, and motor complications? The Patient Question If I have Parkinson’s disease, does this review mean cannabis will not help my tremor or stiffness, and should I stop considering it altogether? The Bottom Line The review’s best-supported conclusion is that cannabis is unlikely to improve Parkinson’s motor symptoms specifically. It does not settle whether cannabis has value for non-motor symptoms, and any change in your care should be discussed with your treating clinician rather than decided from this review alone. CED Perspective Lens ## The Same Study Can Mean Different Things Depending on the Question Being Asked Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses. Lens Overview This review changes the conversation most when readers separate the motor-symptom finding for cannabis from the broader, still-open questions about non-motor symptoms and neuroprotection, and when they resist treating one plant compound’s result as representative of every plant-derived option studied. #### What This Means If You Are Living With Parkinson’s If you were hoping cannabis would meaningfully ease tremor, rigidity, or slowness of movement, this review’s Grade A finding is a reason to recalibrate that expectation rather than assume the study is wrong or incomplete. It is not a reason to feel that cannabis has no place in your care at all. Non-motor symptoms such as sleep, pain, and mood were rated inconclusive here, not negative, and separate research has looked at those outcomes directly. The most useful next step is bringing this specific finding to your neurologist so any [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) is framed around realistic, symptom-specific goals. Lens takeaway Use this review to set realistic motor-symptom expectations, not to abandon every cannabis-related conversation with your care team. #### What a Responsible Clinician Can Say About This Finding A responsible clinician can now say, with real confidence, that current evidence does not support cannabis as a motor-symptom therapy in Parkinson’s disease, and can say so without needing to hedge as heavily as before this review existed. A responsible clinician should still leave room for individualized discussion of non-motor symptoms, since this review rated those outcomes inconclusive rather than negative, and should distinguish this motor-symptom finding from separate observational data on pain, sleep, and urinary symptoms. Lens takeaway This review upgrades confidence around motor-symptom counseling without closing the broader clinical conversation. #### Why a Cautious Reader Should Slow Down The published abstract does not break out how many of the 23 total studies specifically involved cannabis, what products or doses were used, or how consistent those cannabis studies were with each other beyond the summary grade. A skeptical reader should also remember that a Grade A rating for ‘no motor benefit’ still depends on the quality of the specific cannabis studies available today, and that could change as more targeted trials are published. Lens takeaway The grade is meaningful, but the underlying cannabis-specific study details deserve a closer look before this is treated as the final word. #### Where the Methodologic Pressure Points Are The biggest pressure point is transparency at the individual-therapy level. A six-therapy review necessarily compresses a lot of study-level detail, including cannabis product type, dosing, and outcome measurement, into a single summary grade. Without access to the full review and its per-study breakdown, it is hard to know whether the cannabis studies included were themselves diverse enough, or too similar in design, to fully justify the top-tier confidence grade. Lens takeaway The summary grade is a strong signal, but the full review’s per-study detail is where a rigorous second read should go next. #### How This Fits With Earlier CED Coverage on Cannabis and Parkinson’s CED Clinic has previously covered preclinical neuroprotection data suggesting cannabis seed compounds may protect dopamine-producing neurons in laboratory models, and an observational study linking [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) to improvements in pain, sleep, and nighttime urination in Parkinson’s patients. Neither of those pieces addressed motor-symptom efficacy directly, so this systematic review does not contradict them. It fills in the motor-symptom question that earlier CED coverage had not yet directly addressed. Lens takeaway This review adds a missing motor-symptom data point rather than overturning CED’s earlier neuroprotection or non-motor symptom coverage. #### What Changes in the Exam Room What changes is the specificity of the counseling conversation. Clinicians can now cite a preregistered systematic review when explaining that cannabis is unlikely to meaningfully improve tremor, rigidity, or bradykinesia. What does not change is the need to ask about a patient’s actual goals. If a patient is using [cannabis for sleep](https://cedclinic.com/unlock-healing-potential-cannabis-audiobook/), pain, or mood rather than motor control, this review’s motor-symptom finding does not directly speak to that use case. Lens takeaway The practical gain is a more precise, goal-specific cannabis conversation, not a blanket recommendation against [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in Parkinson’s disease. #### What Better Evidence Needs Next The field needs cannabis-specific Parkinson’s trials with standardized product formulations, clear dosing, and dedicated non-motor symptom endpoints, since this review’s non-motor rating was inconclusive rather than settled. It would also help future reviewers to publish per-therapy study breakdowns, so readers can see exactly how many cannabis studies fed into the Grade A motor-symptom finding and how those studies were designed. Lens takeaway Cannabis-specific, non-motor-focused Parkinson’s trials are the clearest next step this review points toward. #### How This Review Could Be Distorted, and What It Actually Says Distortion 1: “This proves cannabis is useless for Parkinson’s disease.” False. The review addressed motor symptoms specifically and rated non-motor outcomes inconclusive, not negative. Distortion 2: “Grade A means cannabis is well-studied and works.” False. Grade A here describes confidence in a finding of no motor benefit, not a positive treatment effect. Distortion 3: “All plant-derived therapies are equally unproven.” False. The same review rated Mucuna pruriens Grade A for motor improvement comparable to levodopa, showing the review differentiated clearly between therapies. Lens takeaway The accurate reading is specific and narrow: no motor-symptom benefit for cannabis, graded with high confidence, alongside open non-motor questions. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Cannabis+and+Parkinson%27s+Motor+Symptoms%3A+What+a+New+Systematic+Review+Actually+Shows&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-parkinsons-disease-plant-therapies-review%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-parkinsons-disease-plant-therapies-review%2F) [BlueSky](https://bsky.app/intent/compose?text=Cannabis+and+Parkinson%27s+Motor+Symptoms%3A+What+a+New+Systematic+Review+Actually+Shows%20https%3A%2F%2Fcedclinic.com%2Fcannabis-parkinsons-disease-plant-therapies-review%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Plant-derived therapies in Parkinson’s disease: a systematic review of clinical evidence.](https://pubmed.ncbi.nlm.nih.gov/42489905/) Related Reading at CED Clinic Continue exploring the evidence [Cannabis Neuroprotection in Parkinson’s: What the Evidence Shows](https://cedclinic.com/cannabis-seed-compounds-may-protect-nerve-cells-from-parkinsons-related-damage/) Earlier CED coverage of preclinical data on cannabis seed compounds and dopaminergic neuroprotection, a different question from this review’s motor-symptom grading. [Read the neuroprotection data](https://cedclinic.com/cannabis-seed-compounds-may-protect-nerve-cells-from-parkinsons-related-damage/) [Cannabis for Parkinson’s: Pain, Sleep & Nocturia Data](https://cedclinic.com/medical-cannabis-linked-to-improvements-in-pain-sleep-and-nighttime-urination-in/) An observational study of non-motor symptom improvements in Parkinson’s patients starting [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/), complementary to this review’s inconclusive non-motor rating. [Review the non-motor findings](https://cedclinic.com/medical-cannabis-linked-to-improvements-in-pain-sleep-and-nighttime-urination-in/) [What 102 Systematic Reviews Say About Cannabis for Pain, IBD, and MS](https://cedclinic.com/systematic-review-cannabis-pain-evidence-2026/) A broader CED look at how systematic-review-level cannabis evidence holds up across other conditions, useful context for weighing this Parkinson’s-specific review. [See the broader evidence picture](https://cedclinic.com/systematic-review-cannabis-pain-evidence-2026/) ## Frequently Asked Questions What did this new systematic review actually study? It evaluated the clinical evidence for six plant-derived therapies in Parkinson’s disease, Mucuna pruriens, Apium graveolens, Curcuma longa, Bacopa monnieri, Glycine max, and Cannabis sativa, across 23 included studies, and graded the evidence for each on motor symptoms, non-motor symptoms, and motor complications. Did the review find that cannabis helps Parkinson’s motor symptoms? No. Cannabis sativa was rated Grade A, the review’s highest evidence-quality tier, for showing no motor benefit. Non-motor outcomes for cannabis were rated inconclusive rather than positive or negative. What does a ‘Grade A’ rating mean in this review? The authors were explicit that their grading reflects study hierarchy and methodological rigor, not certainty of clinical effect. For cannabis, Grade A meant strong confidence in an absence of motor benefit, not a positive result. Which plant-derived therapy performed best in this review? Mucuna pruriens, a legume containing levodopa’s natural precursor, received Grade A evidence for motor improvement comparable to levodopa, including increased ON time without worsening dyskinesia, plus Grade B evidence for reducing dyskinesia. How many studies were included in the review overall? Twenty-three included studies evaluated the six plant-derived therapies combined. The abstract does not specify how many of those 23 studies addressed cannabis specifically. Was this review preregistered? Yes. It followed PRISMA 2020 reporting guidelines and was registered in advance with PROSPERO under registration number CRD420261276805. Does this mean Parkinson’s patients should stop using cannabis? Not necessarily, and that would be overreading the review. It addressed motor symptoms specifically. Non-motor outcomes were rated inconclusive, and separate CED-covered research has examined [cannabis for pain](https://cedclinic.com/cannabis-veterans-substance-use-disorder-study/), sleep, and nighttime urination in Parkinson’s patients. Any change in [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) should be discussed with a treating clinician. What other plant compounds were reviewed alongside cannabis? Apium graveolens (celery seed extract), rated Grade B for motor symptoms, sleep, and quality of life; Curcuma longa (turmeric), rated Grade C for autonomic and non-motor symptoms; Bacopa monnieri, rated Grade B for emotional symptoms; and Glycine max (soybean), rated Grade C for increased ON time and reduced dyskinesia. Why did Mucuna pruriens perform better than cannabis in this review? Mucuna pruriens naturally contains levodopa’s precursor molecule, which may explain its levodopa-comparable motor effects. The review graded it separately from cannabis using the same methodology, which is part of why the comparison is informative rather than an apples-to-oranges claim. What should clinicians and patients take away from this review right now? The most defensible takeaway is that current evidence does not support cannabis specifically for Parkinson’s motor symptoms, while non-motor symptom management and cellular neuroprotection remain open, separately evidenced questions worth continued discussion with a treating clinician. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).